Ascendis Pharma (ASND) Misses Q3 EPS by 48c

Ascendis Pharma (NASDAQ: ASND) reported Q3 EPS of (EUR2.88), EUR0.48 worse than the analyst estimate of (EUR2.40). Revenue for the quarter came in at EUR48.03 million versus the consensus estimate of EUR48.91 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance
• TOYO Co., Ltd (TOYO) Misses Q2 EPS by 24c
• Ameramex International, Inc. (AMMX) Reports In-Line Q2 EPS